KW-2871
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage IV Melanoma
Conditions
Stage IV Melanoma
Trial Timeline
Nov 1, 2004 → —
NCT ID
NCT00199342About KW-2871
KW-2871 is a phase 1/2 stage product being developed by Kyowa Kirin for Stage IV Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00199342. Target conditions include Stage IV Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Stage IV Melanoma were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00199342 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Stage IV Melanoma